Literature DB >> 12882919

Diabetogenic potential of human pathogens uncovered in experimentally permissive beta-cells.

Malin Flodström1, Devin Tsai, Cody Fine, Amy Maday, Nora Sarvetnick.   

Abstract

Pancreatic beta-cell antiviral defense plays a critical role in protection from coxsackievirus B4 (CVB4)-induced diabetes. In the present study, we tested the hypothesis that interferon (IFN)-induced antiviral defense determines beta-cell survival after infection by the human pathogen CVB3, cytomegalovirus (CMV), and lymphocytic choriomeningitis virus (LCMV). We demonstrated that mice harboring beta-cells that do not respond to IFN because of the expression of the suppressor of cytokine signaling-1 (SOCS-1) succumb to an acute form of type 1 diabetes after infection with CVB3. Interestingly, the tropism of the virus was altered in SOCS-1 transgenic (Tg) mice, and CVB3 was detected in islet cells of SOCS-1-Tg mice before beta-cell loss and the onset of diabetes. Furthermore, insulitis was increased in SOCS-1-Tg mice after infection with murine CMV, and a minority of the mice developed overt diabetes. However, infection with LCMV failed to cause beta-cell destruction in SOCS-1 Tg mice. These findings suggest that CVB3 can cause diabetes in a host lacking adequate beta-cell antiviral defense, and that incomplete target cell antiviral defense may enhance susceptibility to diabetes triggered by CMV. In conclusion, suppressed beta-cell antiviral defense reveals the diabetogenic potential of two pathogens previously linked to the onset of type 1 diabetes in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12882919     DOI: 10.2337/diabetes.52.8.2025

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

Review 1.  Immunology in the clinic review series; focus on type 1 diabetes and viruses: the innate immune response to enteroviruses and its possible role in regulating type 1 diabetes.

Authors:  K Lind; M H Hühn; M Flodström-Tullberg
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

2.  A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models.

Authors:  Pär G Larsson; Tadepally Lakshmikanth; Olli H Laitinen; Renata Utorova; Stella Jacobson; Maarit Oikarinen; Erna Domsgen; Minni R L Koivunen; Pascal Chaux; Nicolas Devard; Valerie Lecouturier; Jeffrey Almond; Mikael Knip; Heikki Hyöty; Malin Flodström-Tullberg
Journal:  Diabetologia       Date:  2014-11-05       Impact factor: 10.122

3.  Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation.

Authors:  J Hjelmesaeth; S Sagedal; A Hartmann; H Rollag; T Egeland; M Hagen; K P Nordal; T Jenssen
Journal:  Diabetologia       Date:  2004-08-27       Impact factor: 10.122

4.  Previous maternal infection protects offspring from enterovirus infection and prevents experimental diabetes development in mice.

Authors:  P G Larsson; T Lakshmikanth; E Svedin; C King; M Flodström-Tullberg
Journal:  Diabetologia       Date:  2013-01-24       Impact factor: 10.122

5.  Induction of an antiviral state and attenuated coxsackievirus replication in type III interferon-treated primary human pancreatic islets.

Authors:  Katharina Lind; Sarah J Richardson; Pia Leete; Noel G Morgan; Olle Korsgren; Malin Flodström-Tullberg
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

6.  Coxsackievirus B Vaccines Prevent Infection-Accelerated Diabetes in NOD Mice and Have No Disease-Inducing Effect.

Authors:  Virginia M Stone; Marta Butrym; Minna M Hankaniemi; Amir-Babak Sioofy-Khojine; Vesa P Hytönen; Heikki Hyöty; Malin Flodström-Tullberg
Journal:  Diabetes       Date:  2021-09-08       Impact factor: 9.461

7.  PTPN2, a candidate gene for type 1 diabetes, modulates interferon-gamma-induced pancreatic beta-cell apoptosis.

Authors:  Fabrice Moore; Maikel L Colli; Miriam Cnop; Mariana Igoillo Esteve; Alessandra K Cardozo; Daniel A Cunha; Marco Bugliani; Piero Marchetti; Décio L Eizirik
Journal:  Diabetes       Date:  2009-03-31       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.